Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelodysplagias

Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes

Leukemia volume 20, pages 458–462 (2006)Cite this article

Abstract

Aplastic anemia (AA) and hypoplastic myelodysplastic syndromes (hMDS) are often difficult to distinguish. However, an accurate diagnosis is important because the prognosis and treatment of these diseases may differ. CD34+ hematopoietic progenitors are central to the pathogenesis of both disorders; they are the targets of the autoimmune attack in AA and neoplastic transformation in MDS. The aim of this study was to assess whether bone marrow CD34+ cell numbers could be used in differentiating between AA and hMDS. The percentage of bone marrow CD34+ cells was normal or increased (mean −3.5+0.5%, range 1–7%) in 15 of 35 patients studied, and low (mean −0.13±0.02%, range 0.02−0.36%) in 20 of 35 patients. All patients with a normal or increased percentage of CD34+ cells were ultimately diagnosed with hMDS based on the detection of clonal cytogenetic abnormalities or progression to refractory anemia with excess blasts/acute myeloid leukemia. All patients with low marrow CD34+ cell numbers met standard clinical criteria for AA and have not demonstrated neoplastic transformation with follow-up. Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Nand S, Godwin JE . Hypoplastic myelodysplastic syndrome. Cancer 1988; 62: 958–964.

    Article  CAS  PubMed  Google Scholar 

  2. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993; 66: 117–122.

    Article  CAS  PubMed  Google Scholar 

  3. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM . Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91: 612–617.

    Article  CAS  PubMed  Google Scholar 

  4. Tichelli A, Gratwohl A, Nissen C, Signer E, Gysi CS, Speck B . Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood 1992; 80: 337–345.

    CAS  PubMed  Google Scholar 

  5. Brodsky RA, Jones RJ . Aplastic anaemia. Lancet 2005; 365: 1647–1656.

    Article  CAS  PubMed  Google Scholar 

  6. Barrett J, Saunthararajah Y, Molldrem J . Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15–29.

    Article  CAS  PubMed  Google Scholar 

  7. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS . Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129–3135.

    Article  CAS  PubMed  Google Scholar 

  8. Maciejewski JP, Selleri C . Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma 2004; 45: 433–440.

    Article  PubMed  Google Scholar 

  9. Maciejewski JP, Anderson S, Katevas P, Young NS . Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 1994; 87: 227–234.

    Article  CAS  PubMed  Google Scholar 

  10. Orazi A, Albitar M, Heerema NA, Haskins S, Neiman RS . Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol 1997; 107: 268–274.

    Article  CAS  PubMed  Google Scholar 

  11. Rizzo S, Scopes J, Elebute MO, Papadaki HA, Gordon-Smith EC, Gibson FM . Stem cell defect in aplastic anemia: reduced long term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow. Hematol J 2002; 3: 230–236.

    Article  PubMed  Google Scholar 

  12. Young NS, Maciejewsi J . The pathology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372.

    Article  CAS  PubMed  Google Scholar 

  13. Tefferi A, Thibodeau SN, Solberg Jr LA . Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphism. Blood 1990; 75: 1770–1773.

    CAS  PubMed  Google Scholar 

  14. Nilsson L, Astrand-Grundstrom I, Anderson K, Arvidsson I, Hokland P, Bryder D et al. Involvement and functional impairment of the CD34(+)CD38(−)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002; 100: 259–267.

    CAS  PubMed  Google Scholar 

  15. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986; 256: 1749–1757.

  16. Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998; 22: 971–979.

    Article  CAS  PubMed  Google Scholar 

  17. Weir EG, Cowan K, LeBeau P, Borowitz MJ . A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13: 558–567.

    Article  CAS  PubMed  Google Scholar 

  18. Brodsky RA, Sensenbrenner LL, Jones RJ . Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood 1996; 87: 491–494.

    CAS  PubMed  Google Scholar 

  19. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Karp JE et al. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. Ann Intern Med 2001; 135: 477–483.

    Article  CAS  PubMed  Google Scholar 

  20. Rosenfeld S, Follmann D, Nunez O, Young NS . Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003; 289: 1130–1135.

    Article  CAS  PubMed  Google Scholar 

  21. May WS, Sensenbrenner LL, Burns WH, Ambinder R, Carroll MP, Jones RJ et al. BMT for severe aplastic anemia using cyclosporin. Bone Marrow Transplant 1993; 11: 459–464.

    CAS  PubMed  Google Scholar 

  22. Appelbaum FR, Barrall J, Storb R, Ramberg R, Doney K, Sale GE et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987; 15: 1134–1139.

    CAS  PubMed  Google Scholar 

  23. Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, Van Lint MT et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 1996; 81: 418–422.

    CAS  PubMed  Google Scholar 

  24. Socie G, Henry-Amar M, Bacigalupo A, Hows JM, Tichelli A, Ljungman P et al. Malignant tumors occuring after treatment of aplastic anemia. N Engl J Med 1993; 329: 1152–1157.

    Article  CAS  PubMed  Google Scholar 

  25. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95: 1931–1934.

    CAS  PubMed  Google Scholar 

  26. Brodsky RA, Jones RJ . Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common? Leukemia 2004; 18: 1740–1742.

    Article  CAS  PubMed  Google Scholar 

  27. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ . Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699–705.

    Article  CAS  PubMed  Google Scholar 

  28. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304–309.

    Article  CAS  PubMed  Google Scholar 

  29. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A . Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101: 2156–2158.

    Article  CAS  PubMed  Google Scholar 

  30. Howard SC, Naidu PE, Hu XJ, Jeng MR, Rodriguez-Galindo C, Rieman MD et al. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer 2004; 43: 545–551.

    Article  PubMed  Google Scholar 

  31. Khatib Z, Wilimas J, Wang W . Outcome of moderate aplastic anemia in children. Am J Pediatr Hematol Oncol 1994; 16: 80–85.

    CAS  PubMed  Google Scholar 

  32. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C . The 5q− syndrome. Hematology 2004; 9: 271–277.

    Article  CAS  PubMed  Google Scholar 

  33. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004; 18: 113–119.

    Article  CAS  PubMed  Google Scholar 

  34. Marsh JC, Chang J, Testa NG, Hows JM, Dexter TM . In vitro assessment of marrow ‘stem cell’ and stromal cell function in aplastic anaemia. Br J Haematol 1991; 78: 258–267.

    Article  CAS  PubMed  Google Scholar 

  35. Manz CY, Nissen C, Wodnar-Filipowicz A . Deficiency of CD34+ c-kit+ and CD34+38− hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol 1996; 52: 264–274.

    Article  CAS  PubMed  Google Scholar 

  36. Martinez-Jaramillo G, Flores-Figueroa E, Sanchez-Valle E, Gutierrez-Espindola G, Gomez-Morales E, Montesinos JJ et al. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. Leuk Res 2002; 26: 955–963.

    Article  CAS  PubMed  Google Scholar 

  37. Otawa M, Kawanishi Y, Iwase O, Shoji N, Miyazawa K, Ohyashiki K . Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. Leuk Res 2000; 24: 359–366.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Supported in part by National Institutes of Health Grant P01CA70970. WHM is a fellow of the Leukemia Lymphoma Society.

Author information

Authors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

    W H Matsui, R A Brodsky, B D Smith & R J Jones

  2. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    M J Borowitz

Authors
  1. W H Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R A Brodsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B D Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M J Borowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R J Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W H Matsui.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsui, W., Brodsky, R., Smith, B. et al. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 20, 458–462 (2006). https://doi.org/10.1038/sj.leu.2404119

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404119

Keywords

This article is cited by

Search

Advanced search

Quick links